Skip to main content

Table 2 Prevalence of 17 individual Charlson comorbidities at baseline and at the end of the study

From: Effects of longitudinal changes in Charlson comorbidity on prognostic survival model performance among newly diagnosed patients with hypertension

 

Baseline

At End of Study

 

n

%

n

%

Charlson Comorbidities

Myocardial infarction

27,304

(6.02)

53,774

(11.85)

Congestive heart failure

26,041

(5.74)

60,426

(13.32)

Peripheral vascular disease

13,399

(2.95)

33,863

(7.46)

Cerebrovascular disease

23,881

(5.26)

56,297

(12.41)

Hemiplegia or paraplegia

3738

(0.82)

8536

(1.88)

Dementia

8890

(1.96)

31,659

(6.98)

Chronic pulmonary disease

70,227

(15.48)

122,785

(27.06)

Rheumatologic disease

8161

(1.80)

18,223

(4.02)

Peptic ulcer disease

11,674

(2.57)

27,142

(5.98)

Diabetes without chronic complications

31,098

(6.85)

58,389

(12.87)

Diabetes with chronic complications

7503

(1.65)

23,390

(5.16)

Renal disease

10,231

(2.25)

34,560

(7.62)

Any malignancy, including leukemia and lymphoma

26,853

(5.92)

69,637

(15.35)

Metastatic solid tumor

4784

(1.05)

18,231

(4.02)

Mild liver disease

6524

(1.44)

16,860

(3.72)

Moderate or severe liver disease

968

(0.21)

2782

(0.61)

AIDS/HIV

230

(0.05)

407

(0.09)

Number of Charlson Comorbidities

0

285,417

(63.2)

179,802

(39.6)

1-2

140,101

(28.1)

181,353

(40.0)

≥3

28,216

(8.7)

92,579

(20.4)